UY29924A1 - Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables - Google Patents

Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables

Info

Publication number
UY29924A1
UY29924A1 UY29924A UY29924A UY29924A1 UY 29924 A1 UY29924 A1 UY 29924A1 UY 29924 A UY29924 A UY 29924A UY 29924 A UY29924 A UY 29924A UY 29924 A1 UY29924 A1 UY 29924A1
Authority
UY
Uruguay
Prior art keywords
dibenzo
piperazinyl
pharmaceutically acceptable
hydroxyetoxy
etil
Prior art date
Application number
UY29924A
Other languages
English (en)
Inventor
Ellis Wilson
Joan Shaw
Rohini Chitra
Martin Brecher
Marten Vagero
Hans Eriksson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY29924A1 publication Critical patent/UY29924A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos de tratamiento con una composición farmacéutica, más particularmente una composición farmacéutica de liberación sostenida, que comprende 11 (4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina o una sal farmacéuticamente aceptable de la misma, al igual que métodos nuevos y mejorados para tratar una variedad de dolencias y trastornos psicológicos, inclusive, a modo no taxativo, trastornos del humor y trastornos de ansiedad y para tratar uno o más de los síntomas de estos trastornos.
UY29924A 2005-11-18 2006-11-17 Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables UY29924A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73794305P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
UY29924A1 true UY29924A1 (es) 2007-06-29

Family

ID=38048902

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29924A UY29924A1 (es) 2005-11-18 2006-11-17 Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables

Country Status (8)

Country Link
US (2) US20070185080A1 (es)
EP (1) EP1951256A1 (es)
JP (1) JP2009515952A (es)
CN (1) CN101360504A (es)
AR (1) AR056814A1 (es)
TW (1) TW200735878A (es)
UY (1) UY29924A1 (es)
WO (1) WO2007058593A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100178333A1 (en) * 2006-01-25 2010-07-15 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
EP2268283A2 (en) * 2008-03-12 2011-01-05 Dexcel Ltd. Oral modified-release formulations containing thiazepines
EP2285357B8 (en) * 2008-05-30 2014-07-23 UCB Pharma, S.A. Pharmaceutical compositions comprising brivaracetam
CN101912374B (zh) * 2010-08-08 2016-01-20 浙江华海药业股份有限公司 喹硫平缓释片及其制备方法
CA2834713A1 (en) * 2010-12-03 2012-06-07 Anthony Alexander Mckinney Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
CN102525988B (zh) * 2011-01-04 2016-01-06 北京天衡药物研究院 富马酸喹硫平缓释片
CN102218042A (zh) * 2011-05-26 2011-10-19 青岛黄海制药有限责任公司 富马酸喹硫平组合物的缓释片剂及其制备方法
CN104586805A (zh) * 2014-07-08 2015-05-06 上海中西三维药业有限公司 富马酸喹硫平缓释片剂及其制备方法
WO2018204935A1 (en) 2017-05-05 2018-11-08 Canary Speech, LLC Medical assessment based on voice
JP2022514510A (ja) * 2018-12-14 2022-02-14 プラクシス プレシジョン メディスンズ，インコーポレイテッド うつ病の治療方法
BR112022007392A2 (pt) * 2019-10-17 2022-09-20 Hercules Llc Composição de liberação prolongada dispersível e processo para preparar a mesma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US7973043B2 (en) * 2002-07-30 2011-07-05 Peter Migaly Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic

Also Published As

Publication number Publication date
WO2007058593A1 (en) 2007-05-24
US20110319384A1 (en) 2011-12-29
AR056814A1 (es) 2007-10-24
US20070185080A1 (en) 2007-08-09
CN101360504A (zh) 2009-02-04
EP1951256A1 (en) 2008-08-06
JP2009515952A (ja) 2009-04-16
TW200735878A (en) 2007-10-01

Similar Documents

Publication Publication Date Title
UY29924A1 (es) Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables
ECSP099476A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
AR077415A2 (es) Derivados de oxindol sustituido , medicamentos que los comprenden y uso de los mismos
NO20060556L (no) Quetiapinmetabolitt
CR9667A (es) Derivados de benzamida y usos relacionados con los mismos
UY27300A1 (es) Nuevos derivados de quinolina
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
UY27333A1 (es) Nucleótidos 4` sustituidos
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
UY31405A1 (es) "piperidino-dihidrotienopirimidas sustituidas"
UY26926A1 (es) Derivados de la quinolina y quinazolina
SV2008002511A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
PE20070541A1 (es) Compuestos y composiciones que comprenden isoindol-imidas
UY27427A1 (es) Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
ECSP088869A (es) Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica
ECSP066855A (es) Derivados de benceno sustituidos por glucopiranosilo, medicamentos que contienen esos compuestos, su aplicación y procedimiento para su preparación
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
BRPI0416989A (pt) derivados aminopirazole como inibidores gsk-3
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
ITVA20060041A1 (it) Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington
CO6470862A2 (es) Compuestos carboxamida y su uso como inhibidores de calpaina
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
DOP2003000585A (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades
AR034396A1 (es) Compuestos 4-(1r-4-piperidilen)-4h-benzo[4,5]ciclohepta[1,2]-tiofeno-1-a y sus isomeros opticamente activos, un metodo para su sintesis y el uso de dichos compuestos para la manufactura de un medicamento

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120515